RU2017107273A - Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров - Google Patents

Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров Download PDF

Info

Publication number
RU2017107273A
RU2017107273A RU2017107273A RU2017107273A RU2017107273A RU 2017107273 A RU2017107273 A RU 2017107273A RU 2017107273 A RU2017107273 A RU 2017107273A RU 2017107273 A RU2017107273 A RU 2017107273A RU 2017107273 A RU2017107273 A RU 2017107273A
Authority
RU
Russia
Prior art keywords
lymphocyte
individual
level
lymphocytes
cells
Prior art date
Application number
RU2017107273A
Other languages
English (en)
Russian (ru)
Other versions
RU2017107273A3 (enExample
Inventor
Сьюзан М. МАНЗИ
Джозеф М. АХЕРН
Чао-чин ЛЮ
Original Assignee
Аллегени-Сингер Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллегени-Сингер Рисерч Инститьют filed Critical Аллегени-Сингер Рисерч Инститьют
Publication of RU2017107273A publication Critical patent/RU2017107273A/ru
Publication of RU2017107273A3 publication Critical patent/RU2017107273A3/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5052Cells of the immune system involving B-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/5055Cells of the immune system involving macrophages
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514CD4
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517CD8
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104Lupus erythematosus [SLE]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7095Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
RU2017107273A 2014-08-08 2015-08-07 Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров RU2017107273A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462035073P 2014-08-08 2014-08-08
US62/035,073 2014-08-08
PCT/US2015/044372 WO2016023006A1 (en) 2014-08-08 2015-08-07 Anti-lymphocyte autoantibodies as diagnostic biomarkers

Publications (2)

Publication Number Publication Date
RU2017107273A true RU2017107273A (ru) 2018-09-10
RU2017107273A3 RU2017107273A3 (enExample) 2019-01-18

Family

ID=55264686

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017107273A RU2017107273A (ru) 2014-08-08 2015-08-07 Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров

Country Status (7)

Country Link
US (1) US9709564B2 (enExample)
EP (1) EP3177930A1 (enExample)
JP (1) JP2017528734A (enExample)
CN (1) CN107110861A (enExample)
BR (1) BR112017002575B1 (enExample)
RU (1) RU2017107273A (enExample)
WO (1) WO2016023006A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674543B2 (ja) 2015-07-31 2020-04-01 アレゲーニー・シンガー リサーチ インスティチュート 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ
KR101674018B1 (ko) * 2016-05-16 2016-11-08 (주)글로리바이오텍 Cd4, cd8 세포 정보를 이용한 hiv 진단 방법
CA3022850A1 (en) 2016-05-24 2017-11-30 Allegheny-Singer Research Institute Methods and systems using c4 gene copy number and cell-bound complement activation products for identification of lupus and pre-lupus
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1756571T3 (da) * 2004-04-09 2010-12-13 Univ Pittsburgh Fremgangsmåde i realtid til detektering af akut inflammatoriske tilstande
AU2005242719B2 (en) * 2004-05-11 2011-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnosing and monitoring inflammatory diseases by measuring complement components on white blood cells
CA2738952A1 (en) * 2008-10-16 2010-04-22 Cypress Bioscience, Inc. Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases
WO2011099012A1 (en) * 2010-02-12 2011-08-18 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus (sle)
EP2673644B1 (en) * 2011-02-11 2016-02-10 Exagen Diagnostics, Inc. Methods for diagnosing systemic lupus erythematosus
CN102818890A (zh) * 2011-06-10 2012-12-12 苏州卫生职业技术学院 一种检测系统性红斑狼疮患者自身抗体的方法
PT2791675T (pt) * 2011-12-13 2018-07-27 Baxalta Inc Medição de autoanticorpos em condições de baixa condutividade
US20150204866A1 (en) * 2012-08-02 2015-07-23 Sense Proteomic Limited Auto-antigen biomarkers for lupus
WO2014093268A1 (en) * 2012-12-10 2014-06-19 Allegheny-Singer Research Institute Methods and systems for using complement-tagged molecules as biomarkers of disease
JP6400604B2 (ja) 2013-02-08 2018-10-03 アレゲーニー・シンガー リサーチ インスティチュート プレループス診断用バイオマーカーとしての細胞結合性補体活性産物
CN103439517A (zh) * 2013-09-11 2013-12-11 河北省健海生物芯片技术有限责任公司 一种系统性红斑狼疮自身抗体检测装置

Also Published As

Publication number Publication date
JP2017528734A (ja) 2017-09-28
US20160041164A1 (en) 2016-02-11
BR112017002575A2 (pt) 2018-01-30
WO2016023006A1 (en) 2016-02-11
RU2017107273A3 (enExample) 2019-01-18
BR112017002575B1 (pt) 2023-11-07
US9709564B2 (en) 2017-07-18
EP3177930A1 (en) 2017-06-14
CN107110861A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
Vrbensky et al. The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta‐analysis of a diagnostic test
Hassan-Smith et al. High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis
Tembhare et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases
Csernok et al. Current and emerging techniques for ANCA detection in vasculitis
DK2726883T3 (en) Cell-mediated immune response analysis with enhanced sensitivity
Hanly et al. Measurement of autoantibodies using multiplex methodology in patients with systemic lupus erythematosus
JP2018185339A (ja) 希少ではない細胞を用いて希少細胞を検出する方法
WO2011140433A3 (en) Measurement and comparison of immune diversity by high-throughput sequencing
JP2016507066A5 (enExample)
Wang et al. Reduced activated regulatory T cells and imbalance of Th17/activated Treg cells marks renal involvement in ANCA-associated vasculitis
RU2017107273A (ru) Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров
Kuuliala et al. Constitutive STAT3 phosphorylation in circulating CD4+ T lymphocytes associates with disease activity and treatment response in recent-onset rheumatoid arthritis
WO2020141463A3 (en) Systems and methods for analyzing a fluid sample
RU2017115663A (ru) Способы и системы для отличия синдрома раздраженного кишечника от воспалительного заболевания кишечника и глютеновой болезни
Pasoto et al. The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus
Masi et al. Serum acute phase protein and inflammatory cytokine network correlations: comparison of a pre-rheumatoid arthritis and non-rheumatoid arthritis community cohort
Allelein et al. Clinical evaluation of the first automated assay for the detection of stimulating TSH receptor autoantibodies
JP2017528734A5 (enExample)
Mancebo et al. High proportion of CD95+ and CD38+ in cultured CD8+ T cells predicts acute rejection and infection, respectively, in kidney recipients
JP2010286279A (ja) 自己免疫疾患検査用バイオマーカー及び検査方法
Kim et al. Comparison of automated multiplexed bead-based ANA screening assay with ELISA for detecting five common anti-extractable nuclear antigens and anti-dsDNA in systemic rheumatic diseases
Harich et al. Comparison of anti-CCP autoantibodies measurement by ELISA and a bead-based assay in a large patient cohort
Nederby et al. Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia
WO2019075109A1 (en) BIOMARKERS IN AUTOIMMUNE HEPATIC DISEASE
CN106568977A (zh) 血清中sIL‑7R在诊断系统性红斑狼疮肾炎中的应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20190610